Sexually dimorphic metabolic responses to exposure of a high fat diet during pregnancy, lactation and early adulthood in Gipr mice.

Peptides

Department of Clinical Nutrition, German Institute of Human Nutrition, Arthur-Scheunert-Allee 114-116, 14558, Nuthetal, Germany; Department for Endocrinology, Diabetes and Nutrition, Charité - University of Medicine, Hindenburgdamm 30, 12200 Berlin, Germany; German Center for Diabetes Research, Germany. Electronic address:

Published: March 2020

Obesity has a multifactorial origin. It is known that alterations of the intra uterine milieu induce developmental programming effects leading to metabolic diseases in offspring. Obesity is diminished in mice lacking the glucose-dependent insulinotropic polypeptide receptor (Gipr) when exposed to a high fat diet (HFD). We investigated whether Gipr mice are still protected from obesity when additionally exposure to a HFD during pregnancy and lactation occurs. Male and female wild type (WT) and Gipr offspring received either a control/ low fat diet or HFD during pregnancy and lactation and were then either left on this diet or placed on the opposite diet after weaning until 24 weeks of life. Female WT mice showed increased body weight and adiposity when exposed to a HFD during pregnancy and lactation and post-weaning compared to female WT that received the HFD after weaning only. This exacerbated effect of a HFD during pregnancy and lactation was abolished in female Gipr mice. Male Gipr mice were protected from obesity to a much lesser extent. Male Gipr mice exposed to a HFD during pregnancy and lactation and after weaning exhibited significantly increased fed serum glucose compared to Gipr mice exposed to a HFD after weaning only. In female Gipr mice no differences in fed blood glucose were observed between these groups. Our data indicate that female Gipr mice are more protected from obesity. This protection is preserved in female Gipr mice when additional deleterious effects of a HFD occur during fetal development.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.peptides.2019.170250DOI Listing

Publication Analysis

Top Keywords

gipr mice
36
pregnancy lactation
24
hfd pregnancy
20
female gipr
16
fat diet
12
mice protected
12
protected obesity
12
exposed hfd
12
gipr
11
mice
11

Similar Publications

The use of incretin analogues has emerged in recent years as an effective approach to achieve both enhanced insulin secretion and weight loss in type 2 diabetes (T2D) patients. Agonists which bind and stimulate multiple receptors have shown particular promise. However, off target effects, including nausea and diarrhoea, remain a complication of using these agents, and modified versions with optimized pharmacological profiles and/or biased signaling at the cognate receptors are increasingly sought.

View Article and Find Full Text PDF

Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation.

Mol Metab

January 2025

Section of Endocrinology and Investigative Medicine, Imperial College London, United Kingdom. Electronic address:

Objectives: There is renewed interest in targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) for treatment of obesity and type 2 diabetes. G-protein coupled receptor desensitisation is suggested to reduce the long-term efficacy of glucagon-like-peptide 1 receptor (GLP-1R) agonists and may similarly affect the efficacy of GIPR agonists. We explored the extent of pancreatic GIPR functional desensitisation with sustained agonist exposure.

View Article and Find Full Text PDF

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are gut-derived peptide hormones that potentiate glucose-dependent insulin secretion. The clinical development of GIP receptor (GIPR)-GLP-1 receptor (GLP-1R) multi-agonists exemplified by tirzepatide and emerging GIPR antagonist-GLP-1R agonist therapeutics such as maritide is increasing interest in the extra-pancreatic actions of incretin therapies. Both GLP-1 and GIP modulate inflammation, with GLP-1 also acting locally to alleviate gut inflammation in part through anti-inflammatory actions on GLP-1R+ intestinal intraepithelial lymphocytes.

View Article and Find Full Text PDF

Glucagon-like peptide-1 receptor (GLP-1R) and neuropeptide Y receptors (NPYRs) are expressed in reproductive tissues contributing to the regulation of gonadal function. This exploratory study examines the potential impact of their modulation by assessing the effects of exendin-4 (Ex-4) and peptide YY (PYY) (3-36) on endocrine ovaries and adrenals in high-fat diet (HFD) mice. Ex-4 and PYY(3-36) reduced blood glucose and energy intake, with no effects on body weight.

View Article and Find Full Text PDF

Treatment with sitagliptin exacerbates the M2 phenotype in macrophages in vitro.

Int Immunopharmacol

January 2025

Mucosal Health and Immunology Laboratory (MHIL), Center for Natural and Human Science, Federal University of ABC, Santo André, São Paulo, Brazil; Institute of Biomedical Sciences, University of São Paulo, São Paulo, São Paulo, Brazil. Electronic address:

Article Synopsis
  • Macrophages play a crucial role in regulating the immune response both in normal conditions and during inflammation, and sitagliptin, a diabetes drug, has shown potential anti-inflammatory effects.
  • This study investigated how sitagliptin affects macrophage polarization, finding that it enhances the M2 macrophage phenotype while reducing pro-inflammatory markers like TNF-α.
  • Additionally, sitagliptin treatment impacted mitochondrial function in M2 macrophages, leading to lower energy production and reduced ability to engulf particles.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!